Henry Ford Health

Henry Ford Health Scholarly Commons
Nephrology Articles

Nephrology

10-1-2011

Association of sleep-related problems with CKD in the United
States, 2005-2008
Laura Plantinga
Kathryn Lee
Lesley A. Inker
Rajiv Saran
Jerry Yee
Henry Ford Health, JYEE1@hfhs.org

See next page for additional authors

Follow this and additional works at: https://scholarlycommons.henryford.com/nephrology_articles

Recommended Citation
Plantinga L, Lee K, Inker LA, Saran R, Yee J, Gillespie B, Rolka D, Saydah S, Powe NR. Association of sleeprelated problems with CKD in the United States, 2005-2008. American Journal of Kidney Diseases 2011;
58(4):554-564.

This Article is brought to you for free and open access by the Nephrology at Henry Ford Health Scholarly
Commons. It has been accepted for inclusion in Nephrology Articles by an authorized administrator of Henry Ford
Health Scholarly Commons.

Authors
Laura Plantinga, Kathryn Lee, Lesley A. Inker, Rajiv Saran, Jerry Yee, Brenda Gillespie, Deborah Rolka,
Sharon Saydah, and Neil R. Powe

This article is available at Henry Ford Health Scholarly Commons: https://scholarlycommons.henryford.com/
nephrology_articles/246

Original Investigation
Association of Sleep-Related Problems With CKD in the
United States, 2005-2008
Laura Plantinga, ScM,1 Kathryn Lee, DNSc,2 Lesley A. Inker, MD, MS,3
Rajiv Saran, MD,4 Jerry Yee, MD,5 Brenda Gillespie, PhD,6 Deborah Rolka, MS,7
Sharon Saydah, PhD,7 and Neil R. Powe, MD,1 on behalf of the CDC CKD
Surveillance Team*
Background: Sleep-related problems, which have been associated with poor health outcomes, have not
been investigated thoroughly in people with chronic kidney disease (CKD). We examined the prevalence of a
variety of sleep-related problems in persons with and without CKD.
Study Design: National cross-sectional survey (National Health and Nutrition Examination Survey 20052008).
Setting & Participants: Community-based survey of 9,110 noninstitutionalized US civilian residents 20
years or older.
Predictor: CKD, defined as estimated glomerular filtration rate (eGFR) of 15-59 mL/min/1.73 m2 (stages 3
and 4) or eGFR ⱖ60 mL/min/1.73 m2 and albumin-creatinine ratio ⱖ30 mg/g (stages 1 and 2).
Outcome: Sleep quality, defined using self-report in a multi-item sleep questionnaire including items from
previously validated instruments.
Measurements: Albuminuria and eGFR assessed from urine and blood samples; sleep, demographics, and
comorbid conditions assessed using a standardized questionnaire.
Results: Inadequate sleep (ⱕ6 hours per night) differed by CKD severity (37.4%, 43.0%, and 30.9% for no
CKD, CKD stages 1 and 2, and CKD stages 3 and 4, respectively; P ⫽ 0.003). Frequent sleeping pill use (8.4%,
9.9%, and 16.6%), leg symptoms (39.2%, 48.0%, and 50.9%), and nocturia (20.9%, 35.2%, and 43.6%; P ⬍
0.001 for all) also differed by CKD severity. After adjustment for age, sex, race/ethnicity, obesity, diabetes, and
cardiovascular disease, the prevalence of these sleep-related problems remained higher in people with CKD
stages 1 and 2 relative to no CKD. Most other measures of sleep quality, disorder, and functional outcomes did
not differ by CKD.
Limitations: Inability to establish causality and possible unmeasured confounding.
Conclusion: Providers should be aware of early sleep-related CKD manifestations, including inadequate
sleep, leg symptoms, and nocturia, and of the high rate of reported sleep medication use in this population.
Am J Kidney Dis. 58(4):554-564. © 2011 by the National Kidney Foundation, Inc. Published by Elsevier Inc. All
rights reserved.
INDEX WORDS: Chronic kidney disease; renal function; sleep duration; leg symptoms; sleep aids.

he prevalence of sleep-related problems and disorders is high in patients with end-stage renal disease (ESRD),1,2 particularly sleep apnea,3-8 restless legs
syndrome,9,10 and overall poor sleep quality.11,12 However, relatively few studies have examined sleep problems in the considerably larger group of patients with
pre-ESRD chronic kidney disease (CKD). A high prevalence of self-reported and measured sleep disorder has

T

been reported in patients with moderate to severe13-15 or
recently diagnosed16 CKD; similar results have been
reported in pediatric patients with CKD.17-19 Sleeprelated problems have been associated with increased
risk of mortality in the general population20 and specifically in patients with CKD and ESRD.13,21
CKD is a common disease, with a prevalence in
US adults of up to 13%.22 However, ⬍10% of
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patients with early CKD are aware of their disease.23 CKD is fairly silent in its early stages and in
many cases is treated only when symptoms manifest. Previous studies included persons with diagnosed and/or treated CKD who may have had more
severe symptoms leading to diagnosis and treatment. Whether sleep problems in patients with
CKD are related at least in part to these symptoms
cannot be excluded in such studies. Additionally,
most previous studies do not provide direct comparison groups for the assessment of an independent
effect of CKD on sleep. Such comparisons are
especially important given that sleep-related problems are common in the general US population24
and many sleep problems increase with age,25 as
does the risk of developing CKD.
Our study describes and compares the prevalence
of a comprehensive set of self-reported sleep-related
problems in noninstitutionalized US adults 20 years
or older across the spectrum of pre-ESRD CKD (no,
mild, and moderate to severe CKD) using data from
the National Health and Nutrition Examination Survey (NHANES). We also examined whether differences in symptom prevalence persisted after adjustment for likely confounders.

METHODS
Study Design
The NHANES is conducted by the National Center for Health
Statistics of the US Centers for Disease Control and Prevention
and consists of a standardized in-home interview followed by
physical examination and blood and urine collection at a mobile
examination center. NHANES is a representative sample of
noninstitutionalized US civilian residents.26 This analysis was
limited to 9,110 NHANES 2005-2008 participants who met the
inclusion criteria: 20 years or older, respondent to the sleep
questionnaire, and with available serum creatinine and urine
albumin and creatinine measurements. Those who were pregnant or had an estimated glomerular filtration rate (eGFR) ⬍15
mL/min/1.73 m2 (n ⫽ 1,370) were excluded. All participants
gave written informed consent. The protocol was approved by
the National Center for Health Statistics Research Ethics Review Board.

Measurements
As part of the home interview portion of NHANES 20052008, interviewers administered a questionnaire27 pertaining to
sleep habits and sleep-related problems (Table 1), including
items from 2 previously validated instruments: the Sleep Heart
Health Study Sleep Habits Questionnaire28 and the Functional
Outcomes of Sleep Questionnaire,29,30 through a computerassisted personal interviewing system. Nocturia was assessed
during the same home interview session using a separate
questionnaire. During the interviews, data were collected regarding self-reported demographics (age, sex, and race/ethnicity),
socioeconomic status and health care access (education, insurance, and income), and health status and conditions (selfreported diagnosis of diabetes, hypertension, and cardiovascular disease [CVD]; self-reported smoking; self-rating of current
Am J Kidney Dis. 2011;58(4):554-564

health [health status]; and depressive symptoms from the Patient Health Questionnaire 9,31 a validated clinical depression
screening tool). Prescription medications were recorded by the
interviewer from the bottles provided by the participant, and
sleep aids, diuretics, and psychotropic medications were extracted from these data.
Serum creatinine was measured using the modified kinetic
method of Jaffé. Urine albumin and creatinine were measured
using frozen spot urine specimens with a solid-phase fluorescence
immunoassay and modified Jaffé kinetic method in the same
laboratory, respectively. Height, weight, and blood pressure (at
least 3 auscultatory measurements) were measured during the
examination.26

Deﬁnitions
Sleep
Total hours of sleep were dichotomized by 6 or fewer or 7 or
more hours per night according to National Sleep Foundation
guidelines for adult sleep duration32; 9 hours or more also was
examined separately as above the range for optimal sleep (7-8
hours).33,34 Sleep-onset latency was categorized as 30 or fewer or
30 or more minutes in primary analyses; 5 minutes or less also was
examined as an indicator of severe sleep deprivation.35 Snoring
and stopping breathing were considered habitual if reported at least
once per week. Sleep problems were considered frequent if reported “often” or more (at least 5 times/mo). Nocturia was defined
as reported urination 2 times or more per night. Functional Outcomes of Sleep Questionnaire items29,30 were summarized using
mean scores.

Chronic Kidney Disease
CKD was defined as either decreased kidney function or elevated albuminuria. eGFR was calculated according to the isotopedilution mass spectrometry–traceable 4-variable MDRD (Modification of Diet in Renal Disease) Study equation.36 Serum creatinine
levels were corrected for different analyzers in different years.37,38
Albuminuria was defined as a single urinary albumin-creatinine
ratio ⱖ30 mg/g (microalbuminuria). Definitions of CKD stages39
were modified as no CKD, eGFR ⱖ60 mL/min/1.73 m2 and no
albuminuria; stages 1 and 2 (mild CKD), eGFR ⱖ60 mL/min/1.73 m2
and the presence of albuminuria; and stages 3 and 4 (moderate to
severe CKD), eGFR of 15-59 mL/min/1.73 m2.

Other Deﬁnitions
Self-reported diseases were defined as answers of yes to the
question, “Have you ever been told by a doctor or other health
professional that you have [disease or condition]?” Self-reported
CVD was defined as an answer of yes to any of coronary artery
disease, angina, myocardial infarction, stroke, or congestive heart
failure. Hypertension was defined using self-report or measured
systolic or diastolic blood pressure ⱖ140 or ⱖ90 mm Hg, respectively. Obesity was defined as a measured body mass index ⱖ30
kg/m2. Depressive symptoms were defined as at least 5 positive
responses on the Patient Health Questionnaire-9, including the
items “little or no interest or pleasure in doing things” and “feeling
down/depressed, or hopeless,” along with at least some reported
functional impairment.

Statistical Methods
Selected participant characteristics were compared across
CKD categories using 2 and analysis of variance for categorical and continuous variables, respectively. Excluded participants also were compared with those included in the study by
these characteristics. Unadjusted and adjusted prevalences of
555
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Table 1. Sleep Survey Items, NHANES 2005-2008
Measure
Total hours of sleep

Item

Possible Responses

“How much sleep do you usually get at night on weekdays or
workdays?”

Any no. of h, with upper limit of 12
Any no. of min, with upper limit of 60

Sleep onset

“How long does it usually take you to fall asleep at bedtime?”

Snoring

“In the past 12 months, how often did you snore while you were
sleeping?”

Apnea

“In the past 12 months, how often did you snort, gasp, or stop
breathing while you were sleeping?”

Diagnosed trouble sleeping

“Have you ever been told by a doctor or other health professional
that you have trouble sleeping?”

Diagnosed sleep disorder

“Have you ever been told by a doctor or other health professional
that you have a sleep disorder?”

Yes, no

“What was the sleep disorder?”

Sleep apnea, insomnia, restless legs, other

Trouble falling asleep

“In the past month, how often have you had trouble falling asleep?”

Waking up at night

“In the past month, how often did you wake up at night and have
trouble getting back to sleep?”

Waking too early

“In the past month, how often did you wake up too early in the
morning and were unable to get back to sleep?”

Daytime unrest

“In the past month, how often did you feel unrested during the day,
no matter how many hours of sleep you had?”

Daytime sleepiness

“In the past month, how often did you feel excessively or overly
sleepy during the day?”

Insufficient sleep

“In the past month, how often did you not get enough sleep?”

Sleeping pill use

“In the past month, how often did you take sleeping pills or other
medication to help you sleep?”

Leg jerks

“In the past month, how often did you have leg jerks while trying to
sleep?”

Leg cramps

“In the past month, how often did you have leg cramps while trying
to sleep?”

Nocturiaa

“During the past 30 days, how many times per night did you most
typically get up to urinate, from the time you went to bed at night
until the time you got up in the morning?”

Sleep-related difficulty with
concentrationb

Sleep-related difficulty with concentrationb

Sleep-related difficulty with
memoryb

“Do you have difficulty remembering things because you are
sleepy or tired?”

Sleep-related difficulty with
eatingb

“Do you have difficulty finishing a meal because you become
sleepy or tired?”

Sleep-related difficulty with
hobbyb

“Do you have difficulty working on a hobby, for example, sewing,
collecting, gardening, because you are sleepy or tired?”

Sleep-related difficulty with
transportationb

“Do you have difficulty getting things done because you are too
sleepy or tired to drive or take public transportation?”

Sleep-related difficulty with
financesb

“Do you have difficulty taking care of financial affairs and doing
paperwork (for example, paying bills or keeping financial
records) because you are sleepy or tired?”

Sleep-related difficulty with
workb

“Do you have difficulty performing employed or volunteer work
because you are sleepy or tired?”

Sleep-related difficulty with
telephoneb

“Do you have difficulty maintaining a telephone conversation
because you become sleepy or tired?”

Never, rarely (1-2 nights/wk), occasionally
(3-4 nights/wk), frequently (ⱖ5 nights/wk)
Yes, no

Never; rarely (1⫻/mo); sometimes (2-4⫻/
mo); often (5-15⫻/mo); almost always
(16-30⫻/mo)

0-4 or ⱖ5

Do not do this activity for other reasons; no
difficulty; yes, a little difficulty; yes,
moderate difficulty; yes, extreme difficulty

Abbreviation: NHANES, National Health and Nutrition Examination Survey.
Adapted from the NHANES sleep questionnaire.27
From kidney and urological conditions survey.
b
Functional Outcomes of Sleep Questionnaire29 preface: “The purpose of this next set of questions is to find out if you generally have difficulty carrying
out certain activities because you are too sleepy or tired. When the words ‘sleepy’ and ‘tired’ are used, it means the feeling that you can’t keep your eyes
open, your head is droopy, that you want to ‘nod off’ or that you feel the urge to take a nap. The words do not refer to the tired or fatigued feeling you may
have after you have exercised.”27
a

sleep-related problems were calculated by CKD category, and
variance of proportions was estimated using Taylor series
linearization. Adjusted odds ratios, prevalence estimates, and P
values were calculated using multivariable logistic regression
and predictive margin estimation,40 with adjustment for covariates that were chosen for both evidence of confounding and for
parsimony. Sensitivity analyses with further covariates (depres556

sion, alcohol intake, and use of diuretics or psychotropics) and
CKD defined by GFR estimated using the CKD-EPI (CKD
Epidemiology Collaboration) equation41 also were performed.
All analyses were performed using the svy commands in Stata,
version 10.0 (www.stata.com), to account for study design
weights, strata, and primary sampling units. Statistical significance was set at P ⬍ 0.05.
Am J Kidney Dis. 2011;58(4):554-564
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Table 2. Characteristics of 2005-2008 US Population Sample by CKD Status
Characteristic

Total (N ⴝ 9,110) No CKD (n ⴝ 7,305) CKD Stage 1 or 2 (n ⴝ 875) CKD Stage 3 or 4 (n ⴝ 930)

% of total
Demographics
Age (y)
Sex
Men
Women
Race/ethnicityb
Non-Hispanic white
Non-Hispanic black
Mexican-American
Socioeconomic status
Education
⬍High school
⬎High school
Household income
⬍$20,000
$20-$44,999
$45-$74,999
⬎$75,000
Insurance
Not insured
Insured
Clinical status
Smoking
Every day
Sometimes/not at all
Body mass index
ⱖ30 kg/m2
⬍30 kg/m2
Diabetes (self-reported)
Yes
No
Hypertensionc
Yes
No
CVD (self-reported)
Yes
No
Current health status (self-reported)
Good/fair/poor
Very good or excellent
Depression
Symptomatic by PHQ-9
Not symptomatic by PHQ-9
No. of alcoholic drinks/wk
Diuretic use
Yes
No
Psychotropic use
Yes
No
Laboratory Parameters
eGFR (mL/min/1.73 m2)
Serum creatinine (mg/dL)
UACR (mg/g)

Pa

100

84.6 (83.1-85.9)

7.3 (6.6-8.0)

8.2 (7.1-9.4)

—

47.2 (46.3-48.0)

44.7 (44.0-45.4)

52.3 (50.8-53.7)

68.4 (66.5-70.4)

⬍0.001
⬍0.001

49.8 (48.9-50.7)
50.2 (49.3-51.1)

51.3 (50.3-52.4)
48.7 (47.6-49.7)

45.2 (40.5-49.9)
54.8 (50.1-59.5)

38.4 (34.3-42.5)
61.6 (57.5-65.7)

71.7 (66.9-76.1)
10.6 (8.2-13.5)
8.1 (6.4-10.2)

71.1 (66.3-75.5)
10.6 (8.2-13.6)
8.4 (6.6-10.6)

62.4 (54.9-69.2)
14.7 (11.5-18.6)
10.1 (8.1-12.6)

86.1 (82.0-89.3)
6.6 (4.6-9.4)
2.5 (1.6-3.8)

18.8 (16.7-21.2)
81.2 (78.9-83.3)

17.7 (15.4-20.2)
82.3 (79.8-84.6)

27.5 (24.4-30.8)
72.6 (69.2-75.6)

23.1 (19.4-27.2)
77.0 (72.8-80.6)

15.1 (13.6-16.9)
27.7 (25.3-30.3)
24.2 (22.5-25.9)
33.0 (29.8-36.3)

13.6 (12.1-15.4)
26.7 (24.2-29.4)
24.5 (22.7-26.5)
35.1 (31.8-38.6)

22.9 (20.2-25.7)
33.9 (29.7-38.4)
20.7 (16.4-25.8)
22.5 (18.5-27.1)

24.2 (20.3-28.5)
32.8 (29.2-36.7)
23.4 (19.7-27.5)
19.6 (15.3-24.9)

18.8 (16.8-21.0)
81.2 (79.0-83.2)

20.3 (18.2-22.7)
79.7 (77.3-81.8)

16.7 (13.5-20.5)
83.3 (79.5-86.5)

5.2 (3.4-7.7)
94.8 (92.3-96.5)

19.9 (18.0-22.0)
80.1 (78.0-82.0)

20.7 (18.5-23.1)
79.3 (76.9-81.5)

22.7 (19.5-26.3)
77.3 (73.7-80.5)

9.4 (7.2-12.1)
90.6 (87.8-92.8)

33.8 (31.9-35.7)
66.2 (64.3-68.1)

32.5 (30.5-34.7)
67.5 (65.3-69.5)

45.1 (39.6-50.8)
54.9 (49.2-60.5)

36.6 (33.7-39.6)
63.4 (60.4-66.3)

8.3 (7.4-9.2)
91.7 (90.8-92.6)

5.6 (4.9-6.5)
94.4 (93.5-95.1)

25.6 (22.0-29.5)
74.5 (70.5-78.1)

20.3 (16.7-24.5)
79.7 (75.6-83.3)

42.0 (40.1-44.0)
58.0 (56.0-59.9)

37.3 (35.1-39.5)
62.7 (60.5-64.9)

61.2 (57.6-64.7)
38.8 (35.3-42.4)

74.2 (70.4-77.6)
25.9 (22.4-29.6)

8.5 (7.6-9.5)
91.5 (90.5-92.4)

5.8 (5.1-6.6)
94.2 (93.4-94.9)

15.2 (12.4-18.6)
84.8 (81.4-87.6)

30.4 (25.6-35.6)
69.6 (64.4-74.4)

51.0 (48.6-53.4)
49.0 (46.6-51.4)

48.6 (46.0-51.1)
51.4 (48.9-54.0)

67.8 (63.3-72.0)
32.2 (28.0-36.8)

61.4 (57.0-65.6)
38.6 (34.4-43.0)

5.2 (4.5-6.0)
94.8 (94.0-95.5)
3.9 (3.6-4.3)

5.0 (4.3-5.8)
95.0 (94.2-95.7)
4.1 (3.7-4.5)

8.0 (5.8-10.9)
92.0 (89.1-94.2)
3.5 (2.6-4.5)

4.4 (3.1-6.2)
95.6 (93.8-96.9)
2.0 (1.7-2.4)

6.1 (5.4-6.9)
93.9 (93.1-94.7)

5.2 (4.4-6.2)
94.8 (93.8-95.6)

6.3 (4.7-8.4)
93.8 (91.6-95.4)

14.5 (12.0-17.5)
85.5 (82.5-88.0)

3.0 (2.5-3.4)
97.0 (96.6-97.5)

2.7 (2.3-3.2)
97.3 (96.8-97.7)

3.5 (2.2-5.5)
96.5 (94.5-97.8)

4.8 (3.0-7.5)
95.2 (92.5-97.0)

87.9 (86.5-89.3)
0.88 (0.87-0.89)
35.6 (29.9-41.3)

91.2 (90.1-92.3)
0.85 (0.84-0.85)
8.1 (7.8-8.3)

92.1 (89.7-94.6)
0.82 (0.80-0.84)
213.9 (171.5-256.4)

49.6 (48.6-50.5)
1.29 (1.26-1.31)
162.5 (108.4-216.7)

⬍0.001

⬍0.001

⬍0.001

⬍0.001

0.001

⬍0.001

⬍0.001

⬍0.001

⬍0.001

⬍0.001

0.006

⬍0.001
⬍0.001

0.03

⬍0.001
⬍0.001
⬍0.001

Note: Values shown are percentage or mean (95% confidence interval). Conversion factors for unit: eGFR in mL/min/1.73 m2, ⫻0.01667; serum
creatinine in mg/dL to mol/L, ⫻88.4.
Abbreviations: CKD, chronic kidney disease; CVD, cardiovascular disease; eGFR, estimated glomerular filtration rate; PHQ-9, Patient Health
Questionnaire 9; UACR, urine albumin-creatinine ratio.
a
Across CKD severity categories, by 2 (categorical variables) and analysis of variance (continuous variables) tests.
b
Other race/ethnicity not shown due to small sample sizes, but individuals in “other” category are included in all analyses.
c
Self-reported or measured blood pressure ⱖ140/ⱖ90 mm Hg.

Am J Kidney Dis. 2011;58(4):554-564
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Table 3. Crude Prevalence of Sleep-Related Problems by CKD Status
No CKD (n ⴝ 7,305)

CKD Stage 1 or 2 (n ⴝ 875)

CKD Stage 3 or 4 (n ⴝ 930)

Total sleep time
ⱖ7 h
ⱕ6 h

62.6 (60.3-64.9)
37.4 (35.1-39.7)

57.1 (52.1-61.9)
43.0 (38.2-47.9)

69.1 (65.0-73.0)
30.9 (27.0-35.1)

Sleep onset
⬍30 min
ⱖ30 min

64.3 (62.3-66.2)
35.7 (33.8-37.7)

62.3 (57.9-66.5)
37.7 (33.5-42.1)

67.6 (63.4-71.5)
32.4 (28.5-36.6)

Snoring
Never
ⱖ1⫻/wk

28.4 (26.5-30.3)
71.6 (69.7-73.5)

26.7 (22.6-31.3)
73.3 (68.7-77.4)

29.5 (26.0-33.3)
70.5 (66.7-74.0)

Stop breathing
Never
ⱖ1⫻/wk

79.1 (77.7-80.4)
20.9 (19.6-22.3)

75.9 (71.8-79.6)
24.1 (20.4-28.2)

80.9 (77.7-83.9)
19.1 (16.2-22.3)

Ever told by physician: trouble sleeping
No
Yes

24.0 (22.9-25.1)
76.0 (74.9-77.1)

30.0 (25.4-35.0)
70.0 (65.0-74.6)

28.3 (25.5-31.4)
71.7 (68.7-74.5)

Ever told by physician: sleep disorder
No
Yes

92.5 (91.9-93.2)
7.5 (6.8-8.2)

89.1 (85.3-92.0)
10.9 (8.0-14.7)

92.3 (90.3-94.0)
7.7 (6.0-9.7)

4.5 (4.0-5.2)
1.4 (1.1-1.7)
0.3 (0.2-0.5)
1.2 (1.0-1.5)

7.6 (5.2-11.1)
0.8 (0.4-1.6)b
0.5 (0.2-1.4)b
1.9 (1.0-3.5)

5.8 (4.3-7.9)
1.1 (0.6-1.9)
0.3 (0.0-1.1)b
0.7 (0.2-1.9)b

Sleep-Related Problem

Pa

0.001

0.2

0.6

0.04

0.002

0.02

Apnea
Insomnia
Restless legs
Other
Trouble falling asleep
⬍5⫻/mo
ⱖ5⫻/mo

82.6 (81.5-83-7)
17.4 (16.3-18.5)

80.8 (77.4-83.8)
19.2 (16.2-22.7)

83.1 (80.3-85.5)
16.9 (14.5-19.8)

Waking at night
⬍5⫻/mo
ⱖ5⫻/mo

79.7 (78.6-80.8)
20.3 (19.2-21.4)

77.5 (73.6-81.0)
22.5 (19.0-26.4)

77.9 (74.9-80.7)
22.1 (19.3-25.1)

Waking early
⬍5⫻/mo
ⱖ5⫻/mo

83.1 (82.0-84.2)
16.9 (15.8-18.0)

82.2 (78.0-85.7)
17.8 (14.3-22.0)

82.9 (78.8-86.4)
17.1 (13.7-21.2)

Feeling unrested during day
⬍5⫻/mo
ⱖ5⫻/mo

73.2 (71.8-74.5)
26.8 (25.5-28.2)

70.4 (65.4-74.9)
29.6 (25.1-34.6)

75.5 (71.6-79.0)
24.5 (21.0-28.4)

Feeling sleepy during day
⬍5⫻/mo
ⱖ5⫻/mo

82.2 (80.9-83.5)
17.8 (16.5-19.1)

78.7 (73.9-82.8)
21.3 (17.2-26.1)

80.7 (77.3-83.6)
19.3 (16.4-22.7)

Not getting enough sleep
⬍5⫻/mo
ⱖ5⫻/mo

73.3 (71.8-74.6)
26.7 (25.4-28.2)

73.8 (69.5-77.7)
26.2 (22.3-30.5)

80.6 (76.9-83.8)
19.5 (16.3-23.1)

Taking sleeping pills
⬍5⫻/mo
ⱖ5⫻/mo

91.6 (90.6-92.5)
8.4 (7.5-9.4)

90.2 (87.1-92.6)
9.9 (7.4-12.9)

83.4 (79.3-86.9)
16.6 (13.2-20.7)

Leg jerks
Never
ⱖ1⫻/wk

77.5 (76.2-78.7)
22.5 (21.3-23.8)

74.3 (70.5-77.8)
25.7 (22.2-29.5)

76.5 (73.1-79.6)
23.5 (20.3-26.9)

Leg cramps
Never
ⱖ1⫻/wk

70.6 (68.5-72.7)
29.4 (27.3-31.5)

60.4 (55.8-64.8)
39.6 (35.2-44.2)

56.3 (51.8-60.6)
43.7 (39.4-48.2)

0.01
0.3
0.6
0.2
0.5

0.3

0.9

0.2

0.2

0.004

⬍0.001

0.2

⬍0.001

(Continued)
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Table 3 (Cont’d). Crude Prevalence of Sleep-Related Problems by CKD Status
No CKD (n ⴝ 7,305)

CKD Stage 1 or 2 (n ⴝ 875)

CKD Stage 3 or 4 (n ⴝ 930)

Combined leg symptomsc
No
Yes

60.8 (58.9-62.8)
39.2 (37.2-41.1)

52.0 (48.1-55.9)
48.0 (44.1-51.9)

49.1 (44.9-53.3)
50.9 (46.7-55.1)

Nocturia
Urinate 0-1⫻/night
Urinate ⱖ2⫻/night

79.1 (77.1-80.9)
20.9 (19.1-22.9)

64.8 (61.1-68.3)
35.2 (31.7-38.9)

56.4 (52.2-60.5)
43.6 (39.5-47.8)

Mean FOSQ scored
⬍0.5
ⱖ0.5

88.2 (87.2-89.2)
11.8 (10.8-12.8)

84.2 (81.3-86.8)
15.8 (13.2-18.7)

88.7 (85.2-91.5)
11.3 (8.5-14.8)

Sleep-Related Problem

Pa

⬍0.001

⬍0.001

0.04

Note: Values shown are percentage reporting sleep-related problem (95% confidence interval). Based on National Health and
Nutrition Examination Survey 2005-2008.
Abbreviations: CKD, chronic kidney disease; FOSQ, Functional Outcomes of Sleep Questionnaire.
a
By 2 test (categorical variables).
b
Unreliable estimate: relative standard error ⱖ30%.
c
Diagnosed restless legs syndrome or leg cramps or jerks at least once per month.
d
Score represents mean of all completed items as listed in Table 1. Scores are on a 0-3 scale, with 0 ⫽ no difficulty, 1 ⫽ a little
difficulty, 2 ⫽ moderate difficulty, and 3 ⫽ severe difficulty; all other responses excluded.

RESULTS
Characteristics of Study Population by CKD
As listed in Table 2, patients with CKD stages 3 and
4 were older and more likely to be women, have insurance, and be nonsmokers than those without CKD.
Patients with CKD stages 1 and 2 were more likely to be
non-Hispanic black than those without CKD and with
CKD stages 3 and 4. Education and income levels and
body mass index were higher in patients without CKD
than those with CKD regardless of severity. Diabetes,
hypertension, and CVD were more frequent with greater
CKD severity. Depressive symptoms did not differ by
CKD severity (Table 2).
Patients included in the study were older and more
likely to be men and have higher income (P ⬍ 0.05
for all) relative to those excluded from the study due
to missing sleep questionnaire or CKD measurements, eGFR ⬍15 mL/min/1.73 m2, or pregnancy.
There were no statistically significant differences between included and excluded samples by body mass
index, smoking status, or other clinical characteristic.
Prevalence of Sleep-Related Problems by CKD
Table 3 lists crude prevalences of sleep-related
problems by survey item and CKD. Patients with
CKD stages 1 and 2 had higher levels of inadequate
sleep (ⱕ6 hours per night) and prolonged sleep-onset
latency (ⱖ30 minutes to fall asleep; not statistically
significant) than those with no CKD or CKD stages 3
and 4. Notably, in those who reported 7 or more hours
of sleep per night, those with CKD also were more
likely to report sleeping 9 or more hours per night
(6.8% for stages 1 and 2 and 6.9% for stages 3 and 4
compared with 2.8% in those without CKD; P ⫽ 0.04;
Am J Kidney Dis. 2011;58(4):554-564

not shown in table). Mean sleep durations were 6.8,
6.7, and 7.2 hours for no CKD, stages 1 and 2, and
stages 3 and 4 (P ⬍ 0.001 by analysis of variance).
The prevalence of sleep-onset latency of 5 minutes or
less (characteristic of severe sleep deprivation) was
high, but did not differ by CKD status (29.0%, 30.4%,
and 27.5% for no CKD, stages 1 and 2, and stages 3
and 4, respectively; not shown in table).
Frequent daytime sleepiness and frequent sleeping
pill use were more frequent in those with CKD (Table 3).
Frequent sleeping pill use also was associated with
shorter sleep duration: 63.4% of patients not reporting
frequent sleeping pill use reported sleeping 7 or more
hours per night compared with 55.7% of those reporting
frequent use (P ⫽ 0.002; not shown in table). Combined
leg symptoms (leg jerks, leg cramps, or diagnosed restless legs syndrome) and nocturia were more frequent
with increasing CKD severity. There were no significant
differences in crude prevalences of any other reported
sleep-related problems by CKD status (Table 3).
Table 4 compares unadjusted prevalences of selected sleep-related problems overall with the prevalence adjusted to US population distributions of the
given covariates (models 1 and 2). Age-, sex-, and
race/ethnicity-adjusted prevalences (model 1) of inadequate sleep, daytime sleepiness, leg-related symptoms, and nocturia were higher in those with CKD
stages 1 and 2 and stages 3 and 4 relative to no CKD.
Adjusted total sleep duration was higher in those with
CKD stages 3 and 4 (7.1 hours; P ⬍ 0.001) relative to
no CKD. Sleeping pill use was no longer statistically
significantly different by CKD status after this adjustment. Further adjustment for common comorbid conditions (obesity, diabetes, and CVD; model 2) showed
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Table 4. Odds Ratios for Selected Sleep-Related Problems by
CKD Status
Model

CKD Stages 1 & 2

CKD Stages 3 & 4

Inadequate Sleep (<6 h sleep per night)
Unadjusted

1.26 (1.05-1.51)

0.75 (0.60-0.93)

Model 1

1.26 (1.04-1.52)

0.81 (0.62-1.05)

Model 2
⫹ Depression
⫹ Alcohol use
⫹ Diuretics
⫹ Psychotropics

1.17 (0.96-1.42)
1.15 (0.95-1.41)
1.14 (0.93-1.39)
1.17 (0.96-1.42)
1.17 (0.96-1.42)

0.75 (0.58-0.98)
0.76 (0.58-0.98)
0.76 (0.58-1.00)
0.75 (0.58-0.98)
0.75 (0.58-0.98)

Model 2, CKD-EPIa

1.17 (0.97-1.41)

0.73 (0.55-0.96)

Daytime Sleepiness (feeling sleepy during the day
>5 ⴛ/mo)
Unadjusted

1.25 (0.95-1.65)

1.11 (0.89-1.39)

Model 1

1.36 (1.02-1.81)

1.34 (1.06-1.70)

Model 2
⫹ Depression
⫹ Alcohol use
⫹ Diuretics
⫹ Psychotropics

1.20 (0.89-1.63)
1.16 (0.86-1.55)
1.22 (0.86-1.73)
1.21 (0.89-1.63)
1.20 (0.89-1.62)

1.22 (0.95-1.57)
1.26 (0.98-1.60)
1.35 (0.97-1.88)
1.22 (0.94-1.57)
1.22 (0.94-1.58)

Model 2, CKD-EPIa

1.20 (0.89-1.61)

1.23 (0.96-1.56)

Frequent Use of Sleep Medications (taking sleeping pills >5ⴛ/mo)
Unadjusted

1.19 (0.86-1.65)

2.16 (1.73-2.70)

Model 1

1.00 (0.71-1.38)

1.18 (0.92-1.51)

Model 2
⫹ Depression
⫹ Alcohol use
⫹ Diuretics
⫹ Psychotropics

0.90 (0.65-1.24)
0.86 (0.62-1.19)
1.07 (0.76-1.49)
0.90 (0.65-1.24)
0.90 (0.65-1.24)

1.06 (0.82-1.35)
1.07 (0.84-1.36)
1.13 (0.86-1.47)
1.05 (0.82-1.35)
1.06 (0.83-1.35)

Model 2, CKD-EPIa

0.91 (0.65-1.28)

0.84 (0.64-1.11)

Combined Leg-Related Sleep Symptoms (leg cramps or jerks
>1ⴛ/mo or diagnosed RLS)
Unadjusted

1.43 (1.23-1.66)

1.61 (1.39-1.86)

Model 1

1.30 (1.10-1.54)

1.17 (1.00-1.35)

Model 2
⫹ Depression
⫹ Alcohol use
⫹ Diuretics
⫹ Psychotropics

1.17 (0.99-1.39)
1.15 (0.97-1.37)
1.20 (0.98-1.46)
1.17 (0.99-1.39)
1.17 (0.99-1.39)

1.10 (0.94-1.29)
1.11 (0.95-1.30)
1.01 (0.81-1.26)
1.10 (0.94-1.29)
1.10 (0.93-1.30)

Model 2, CKD-EPIa

1.17 (0.98-1.40)

1.15 (0.97-1.27)

Nocturia (reported urinations >5 ⴛ/night)
Unadjusted

2.06 (1.71-2.47)

2.92 (2.45-3.49)

Model 1

1.54 (1.28-1.86)

1.27 (1.06-1.54)

Model 2
⫹ Depression
⫹ Alcohol use
⫹ Diuretics
⫹ Psychotropics

1.30 (1.07-1.57)
1.26 (1.05-1.52)
1.32 (1.07-1.62)
1.30 (1.07-1.57)
1.30 (1.07-1.57)

1.13 (0.94-1.35)
1.14 (0.95-1.36)
1.21 (0.99-1.49)
1.12 (0.94-1.35)
1.13 (0.94-1.35)

Model 2, CKD-EPIa

1.31 (1.09-1.58)

1.22 (1.02-1.45)

Note: Values shown are odds ratio (95% confidence interval); reference group
is no CKD. Based on National Health and Nutrition Examination Survey 20052008. Model 1, age, sex, and race/ethnicity; model 2, model 1 ⫹ obesity,
diabetes, and cardiovascular disease. Obesity defined as body mass index ⱖ30
kg/m2, and diabetes and cardiovascular disease defined by self-report.
Abbreviations: CKD, chronic kidney disease; CKD-EPI, Chronic Kidney
Disease Epidemiology Collaboration; RLS, restless legs syndrome.
a
CKD status based on estimated glomerular filtration rates calculated using
the CKD-EPI equation instead of the isotope-dilution mass spectrometry–
traceable 4-variable MDRD (Modification of Diet in Renal Disease) Study equation.
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that frequent daytime sleepiness and sleeping pill use
were no longer statistically significant by CKD status;
the prevalence of inadequate sleep was statistically
significantly lower in patients with CKD stages 3 and
4 relative to no CKD, whereas leg symptoms (P ⫽
0.06) and nocturia (P ⫽ 0.01) remained higher in
patients with CKD stages 1 and 2 compared with
those with no CKD.
Further adjustment for depression, alcohol intake,
diuretic use, and psychotropic use did not change
results (Table 4; vs Model 2). Additionally, the prevalence of all sleep-related problems by CKD estimated
using the CKD-EPI equation41 did not substantially
differ (Table 4).
Due to possible effects of sleeping pill use on
symptoms (confounding by indication), we examined
the prevalence of inadequate sleep, leg-related sleep
symptoms, and nocturia by CKD in those reporting
and not reporting regular sleeping pill use (Table 5).
The associations of sleep-related problems in this
subpopulation were not substantially different from
those in the overall population; however, results for
inadequate sleep and daytime sleepiness were most
robust in the frequent sleeping pill users, whereas
results for leg symptoms and nocturia were most
robust in nonfrequent users (Table 5).
Reported Use of Sleep-Inducing and Sleep-Disrupting
Medications by CKD
Although 9.2% (Fig 1A) of the overall study population reported using sleeping pills 5 or more times a
month, only 17.4% of these frequent users reported
having a prescription for sleep medication, and this
prevalence did not differ by CKD status (17.9%,
13.8%, and 16.1% for no CKD, stages 1 and 2, and
stages 3 and 4; Fig 1B). Of note, 11.8% and 7.1% of
patients with CKD stages 1 and 2 and stages 3 and 4
had prescriptions for sleep medications specifically
contraindicated for those with known kidney problems, respectively (ramelteon, zaleplon, and zolpidem; Fig 1B). These proportions represent 70.6%
(CKD stages 1 and 2) and 39.2% (CKD stages 3 and
4) of patients with CKD who had a prescription sleep
medication. As shown in Fig 1C, reported prescription
diuretics and psychotropics, which can disrupt sleep,
were more frequent in those with CKD stage 3 or 4
compared with either no CKD or CKD stage 1 or 2
(not statistically significant).

DISCUSSION
The prevalence of sleep-related problems in the US
population generally was high. Many of the sleep
symptoms examined, including prolonged sleep-onset
latency/trouble falling asleep, frequent waking at night
or too early, sleep-disordered breathing, snoring, diagAm J Kidney Dis. 2011;58(4):554-564
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Table 5. Adjusted Odds Ratios for Selected Sleep-Related Problems by CKD Status and Sleeping Pill Use
<5 Sleeping Pills/mo

Inadequate sleep
Frequent daytime
sleepiness
Combined leg-related
symptoms
Nocturia

>5 Sleeping Pills/mo

No CKD

Stages 1 & 2

Stages 3 & 4

No CKD

Stages 1 & 2

Stages 3 & 4

1.00 (ref)
1.00 (ref)

1.13 (0.90-1.41)
1.14 (0.79-1.64)

0.79 (0.60-1.03)
1.31 (0.96-1.79)

1.00 (ref)
1.00 (ref)

1.93 (1.19-3.11)
1.98 (1.04-3.77)

0.60 (0.34-1.07)
0.95 (0.61-1.46)

1.00 (ref)

1.21 (1.01-1.46)

1.05 (0.88-1.24)

1.00 (ref)

1.04 (0.68-1.58)

1.46 (0.88-2.40)

1.00 (ref)

1.27 (1.07-1.51)

1.11 (0.93-1.33)

1.00 (ref)

1.57 (0.75-3.27)

1.18 (0.67-2.06)

Note: Values shown are adjusted odds ratio (95% confidence interval). Based on National Health and Nutrition Examination Survey
2005-2008. Odds ratios adjusted for age, sex, race/ethnicity, obesity, diabetes, and cardiovascular disease. Obesity defined as body
mass index ⱖ30 kg/m2, and diabetes and cardiovascular disease defined by self-report.
Abbreviations: CKD, chronic kidney disease; ref, reference.

nosed sleep disorders, and functional outcomes of
sleep, did not differ by CKD severity. However,
prevalence estimates for inadequate sleep, frequent
daytime sleepiness, reported use of sleeping pills, leg
symptoms, and nocturia were found to be higher in
patients with early-stage CKD than in those without
CKD. These patterns persisted for inadequate sleep,
leg symptoms, and nocturia after adjustment for demographics, but were not always statistically significant
after adjustment for common comorbid conditions
(obesity, diabetes, and CVD).
We did not find CKD status to be associated with a
higher prevalence of sleep-disordered breathing or
sleep apnea. Sim et al15 found that coded sleep apnea
was associated with severity of CKD in a patient
cohort. Coded sleep apnea likely is a specific but not
necessarily sensitive marker. Additionally, providers
who frequently measure CKD status may be more
likely to test and code for sleep apnea. Here, both
diagnosed sleep apnea and sleep-disordered breathing
were self-reported, and many patients with sleep apnea may be unaware of their condition.
In our study, with the exception of inadequate
sleep, decreased sleep quality in patients with CKD
was explained largely by age, obesity, diabetes, and
CVD. Several previous studies13,14,16,42 have shown a
high prevalence of sleep problems in patients with
moderate to severe CKD. These studies predominantly were of patients with higher stage or diagnosed
CKD, which may explain some differences. Additionally, they used questionnaire items that differ from
those used in NHANES.
We found that inadequate sleep was associated with
mild CKD, but not moderate to severe CKD, relative
to those with no CKD, a pattern that was not explained by the increased age of the population with
moderate to severe CKD. It is possible that early
stages of kidney damage may have more effect on
sleep than subsequently decreased kidney function, or
perhaps more severe CKD leads to more pronounced
Am J Kidney Dis. 2011;58(4):554-564

fatigue, more frequent use of sleeping pills, and/or
greater total hours of sleep regardless of the quality of
the sleep. We found that reported sleep duration of 9
or more hours was increasingly common with CKD
severity. Additionally, further examination of actual
numbers of sleep hours showed that sleep duration
was shorter in patients with CKD stages 1 and 2, but
longer in those with CKD stages 3 and 4 relative to no
CKD.
Both leg symptoms9 and nocturia43 have been
shown to be associated with lower health-related
quality of life. We found that leg symptoms and
nocturia were reported more frequently by patients
with CKD, which was explained largely by age and
comorbid conditions in patients with moderate to
severe and mild CKD versus no CKD. Greater mortality in patients with sleep-related problems in the early
stages of CKD may contribute to the slightly (but not
statistically significantly) higher prevalence of these
symptoms in patients with mild versus moderate to
severe CKD.15 It also is possible that as disease
progresses, persons with CKD become inured to these
symptoms and less likely to report them. The finding
that 45% of patients with CKD stages 3 and 4 report
urinating 2 or more times per night, but 23% report
frequently waking at night, suggests possible unreliability of self-report data and/or adaptation to sleep
disturbances. Finally, it is possible that older individuals with moderate to severe CKD are more likely to
attribute such symptoms (particularly nocturia) to
their age and thus less likely to recognize and report
abnormal symptoms relative to individuals with mild
or no CKD.
A large proportion (⬃9%) of the US population
reported using sleeping pills 5 or more times per
month, although few of these reported having a prescription sleep aid, indicating that most sleeping aids
used were available over the counter. Patients with
moderate to severe CKD reported more frequent sleeping pill use than those without CKD, explained largely
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Figure 1. (A) Reported frequent use (ⱖ5 times per month) of
sleeping pills by chronic kidney disease (CKD) status (P ⬍ 0.001)
and, in reported frequent sleeping pill users, reported current prescriptions for (B) sleep medications and (C) drugs that interfere with
sleep. National Health and Nutrition Examination Survey 20052008. P values by 2 test, not statistically significant for B (P ⫽ 0.13)
and C (P ⫽ 0.28). Contraindicated sleep medications: contraindicated in the presence of kidney disease (from warning labels),
ramelteon, zaleplon, and zolpidem; psychotropic medications, benzodiazepines, theophylline, fluoxetine, and bupropion.

by obesity, diabetes, CVD, and other sequelae of
increasing age. In those with moderate to severe CKD
who used a prescription sleep aid, nearly 25% were
using medications contraindicated for kidney disease,
likely because they and their physicians were unaware
of their disease. Although diuretics commonly were
used, they were not statistically significantly associated with CKD status or nocturia after adjustment for
hypertension.
Although we found several significant associations
between CKD and sleep, most markers of sleep quality examined in this study did not differ by CKD
562

status, including prolonged sleep-onset latency/trouble
falling asleep, frequent waking at night or too early,
sleep-disordered breathing, snoring, and diagnosed
sleep disorders. This contradictory evidence relative
to some previous reports may reflect no true association, differences in ascertainment, and/or self-report
bias. Sleep-disordered breathing and snoring likely
are under-recognized and may not be reliable by
self-report; most (up to 95%) sleep disorders frequently may be undiagnosed44 as well. Additionally,
functional outcomes of sleep generally did not differ
by CKD status, suggesting that regardless of CKD
status, effects of dysfunctional sleep on daytime functioning likely are similar between those with and
without CKD.
There are several limitations of this study that
should be noted. The cross-sectional design precludes
causal inference about CKD and sleep symptoms.
Data from only 2 surveys are available, limiting
adjusted and stratified analyses. Sleep symptoms were
self-reported and thus may be over- or under-reported,
depending on the presence of a sleep partner, individual variation in detecting sleep issues, and possible
recall bias. Although we adjusted for confounders, we
know that patients included in the study were more
likely to be older, men, non-Hispanic white, and
wealthier than those excluded because of missing
measurements. Thus, our estimates of the prevalence
of sleep-related problems may not be representative
of the entire CKD population. Data for specific kidney
issues, such as pruritis and chronic pain45 and caffeine
use, all of which might affect sleep, were not available
in this survey. Measures of leg symptoms may have
lacked some sensitivity given that patients with CKD
may have sensations in legs (eg, “creepy-crawly”)
that are not attributable to leg cramps or jerks or are
not recognized as restless legs syndrome, but which
nonetheless may interfere with sleep. Over-thecounter, off-label, and herbal drugs for sleep were not
tracked. The high prevalence of many sleep problems
in the general population may make it difficult to
determine a CKD-specific effect. Finally, misclassification of CKD due to single measurements of eGFR
and albuminuria is possible.
However, our study also has several important
advantages over previous studies. It is a large nationally representative study examining a comprehensive
range of sleep-related problems in patients with CKD
before ESRD. CKD was defined regardless of whether
the disease is recognized, diagnosed, or treated, all of
which may affect sleep symptoms. Additionally, we
were able to compare prevalence with that in similar
persons without CKD to determine whether CKD had
an independent effect on sleep after adjustment for
Am J Kidney Dis. 2011;58(4):554-564
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other factors strongly related to both CKD and sleep,
including age, sex, obesity, diabetes, and CVD.
Although the association between CKD and sleeprelated problems in the United States might not be as
strong as previously thought after adjustment for age
and comorbid conditions common in patients with
CKD, we note that inadequate sleep, leg symptoms,
and nocturia were reported more frequently by patients with CKD in its early stages than in those
without CKD. Primary care providers, who are most
likely to identify and treat early-stage CKD, should be
aware that sleep-related problems likely are common
in all their patients and certain sleep symptoms may
be even more prevalent in their patients with CKD.
Providers also should be aware that many patients
with CKD report using unprescribed sleep aids and
should query patients about their use of herbal, offlabel, and over-the-counter drugs for sleep to ensure
their safety and prevent kidney-related complications.
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